logo

China suspends sales of leukemia drug

Monday, 9 July 2007


BEIJING, July 8 (AP): China's drug watchdog announced Saturday it has suspended the sale of a drug used to treat acute leukemia and rheumatoid arthritis in the latest move to hit the country's scandal-ridden drug industry.
The Chinese government has been trying to toughen it drug regulation amid mounting criticism - at home and aboard - that the quality of its drug, food and other products is poorly regulated.
In the past week alone, a former department head at the State Food and Drug Administration was sentenced to death on bribery charges, and it was announced that production licenses of five drug makers had been pulled over the last year and that 128 others had been penalized.
The moves come as U.S. regulators ordered a recall of three more Chinese-made products deemed dangerous to children, part of a lengthening list of recent U.S. government actions to ban, recall or restrict Chinese imports - from juice to toothpaste - suspected of containing high levels of toxins.
In a notice posted late Saturday on its Web site, the State Food and Drug Administration said it had suspended the sale of methotrexate made by Shanghai Hualian Pharmaceutical Co. Ltd.
The statement said it caused adverse reactions in several young leukemia patients in hospitals of Guangxi autonomous region in southern China and the eastern financial center of Shanghai.
"Some of the children have felt pain in their legs and some have experienced difficulty in walking after being injected with the methotrexate drug numbered 070403A and 070403B," the statement said.
On Friday, a Beijing court sentenced Cao Wenzhuang, a department director at the State Food and Drug Administration, to death with a two-year reprieve on charges of accepting bribes and neglecting official duties, according to his lawyer, Gao Zicheng.